Testis cancer
Identifieur interne : 001C88 ( Pmc/Curation ); précédent : 001C87; suivant : 001C89Testis cancer
Auteurs : Omar Khan ; Andrew ProtheroeSource :
- Postgraduate Medical Journal [ 0032-5473 ] ; 2007.
Abstract
Testis cancer is an increasing problem, especially in northern European male populations. However, survival has improved dramatically over one generation. Environmental factors may have a role in the aetiology with high oestrogen concentrations implicated. Testis cancer is subdivided between seminoma and non‐seminoma. At presentation, a testicular lump is the most common finding and radical inguinal orchidectomy is recommended for most. Further multidisciplinary management is determined by histological subtype and stage and involves chemotherapy, radiotherapy and surgery, with many patients only undergoing surveillance. There is increasing emphasis on reducing toxicity of treatments in long term survivors. Treatment refractory testis cancer remains a significant challenge.
Url:
DOI: 10.1136/pgmj.2007.057992
PubMed: 17916870
PubMed Central: 2600126
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001C89
Links to Exploration step
PMC:2600126Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Testis cancer</title><author><name sortKey="Khan, Omar" sort="Khan, Omar" uniqKey="Khan O" first="Omar" last="Khan">Omar Khan</name></author><author><name sortKey="Protheroe, Andrew" sort="Protheroe, Andrew" uniqKey="Protheroe A" first="Andrew" last="Protheroe">Andrew Protheroe</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">17916870</idno><idno type="pmc">2600126</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600126</idno><idno type="RBID">PMC:2600126</idno><idno type="doi">10.1136/pgmj.2007.057992</idno><date when="2007">2007</date><idno type="wicri:Area/Pmc/Corpus">001C89</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001C89</idno><idno type="wicri:Area/Pmc/Curation">001C88</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001C88</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Testis cancer</title><author><name sortKey="Khan, Omar" sort="Khan, Omar" uniqKey="Khan O" first="Omar" last="Khan">Omar Khan</name></author><author><name sortKey="Protheroe, Andrew" sort="Protheroe, Andrew" uniqKey="Protheroe A" first="Andrew" last="Protheroe">Andrew Protheroe</name></author></analytic><series><title level="j">Postgraduate Medical Journal</title><idno type="ISSN">0032-5473</idno><idno type="eISSN">1469-0756</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Testis cancer is an increasing problem, especially in northern European male populations. However, survival has improved dramatically over one generation. Environmental factors may have a role in the aetiology with high oestrogen concentrations implicated. Testis cancer is subdivided between seminoma and non‐seminoma. At presentation, a testicular lump is the most common finding and radical inguinal orchidectomy is recommended for most. Further multidisciplinary management is determined by histological subtype and stage and involves chemotherapy, radiotherapy and surgery, with many patients only undergoing surveillance. There is increasing emphasis on reducing toxicity of treatments in long term survivors. Treatment refractory testis cancer remains a significant challenge.</p></div></front></TEI><pmc article-type="review-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Postgrad Med J</journal-id><journal-title>Postgraduate Medical Journal</journal-title><issn pub-type="ppub">0032-5473</issn><issn pub-type="epub">1469-0756</issn><publisher><publisher-name>BMJ Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17916870</article-id><article-id pub-id-type="pmc">2600126</article-id><article-id pub-id-type="publisher-id">pj57992</article-id><article-id pub-id-type="doi">10.1136/pgmj.2007.057992</article-id><article-categories><subj-group subj-group-type="heading"><subject>Urology</subject></subj-group></article-categories><title-group><article-title>Testis cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Omar</given-names></name></contrib><contrib contrib-type="author"><name><surname>Protheroe</surname><given-names>Andrew</given-names></name></contrib></contrib-group><aff><bold>Omar Khan</bold>,<bold>Andrew Protheroe</bold>, Cancer Research UK, Medical Oncology Unit, Churchill Hospital, Oxford, UK</aff><author-notes><corresp>Correspondence to: Dr Omar Khan<break></break>Cancer Research UK, Medical Oncology Unit, Churchill Hospital, Oxford OX3 7LJ, UK; omar.khan@cancer.org.uk</corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2007</year></pub-date><volume>83</volume><issue>984</issue><fpage>624</fpage><lpage>632</lpage><history><date date-type="received"><day>26</day><month>1</month><year>2007</year></date><date date-type="accepted"><day>16</day><month>5</month><year>2007</year></date></history><permissions><copyright-statement>Copyright © 2007 The Fellowship of Postgraduate Medicine</copyright-statement></permissions><abstract><p>Testis cancer is an increasing problem, especially in northern European male populations. However, survival has improved dramatically over one generation. Environmental factors may have a role in the aetiology with high oestrogen concentrations implicated. Testis cancer is subdivided between seminoma and non‐seminoma. At presentation, a testicular lump is the most common finding and radical inguinal orchidectomy is recommended for most. Further multidisciplinary management is determined by histological subtype and stage and involves chemotherapy, radiotherapy and surgery, with many patients only undergoing surveillance. There is increasing emphasis on reducing toxicity of treatments in long term survivors. Treatment refractory testis cancer remains a significant challenge.</p></abstract><kwd-group><kwd>testis cancer</kwd><kwd>epidemiology</kwd><kwd>aetiology</kwd><kwd>treatment</kwd><kwd>long‐term toxicity</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C88 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 001C88 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:2600126
|texte= Testis cancer
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:17916870" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |